Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

FIT-HF Semaglutide Trial Protocol

FIT-HF will compare semaglutide with intensive diet-based weight loss in 100 adults with obesity and reduced-ejection-fraction heart failure.

Why we wrote this. FIT-HF asks a useful active-comparator question, but this publication is a protocol and contains no efficacy result.

In this article (4 sections)
  1. Why FIT-HF is being run
  2. How the trial is designed
  3. What FIT-HF will measure
  4. What we do not know

FIT-HF is a randomized trial designed to compare two ways of producing intentional weight loss in adults with obesity and stable heart failure with reduced ejection fraction, or HFrEF: weekly semaglutide and an intensive low-calorie diet program. The 2026 publication is the study protocol. It reports what investigators plan to measure, not whether either strategy improves exercise capacity or heart failure outcomes[1].

That protocol status is essential. It lets readers assess the planned methods before results are known, but it contains no between-group efficacy estimate, adverse-event rate or conclusion about which approach is better.

Why FIT-HF is being run

Obesity is common in HFrEF, but deliberate weight loss in this population poses questions about exercise capacity, body composition and safety. Trials in obesity-related heart failure with preserved ejection fraction have produced encouraging symptom and function findings for incretin therapies. The FIT-HF authors say evidence in reduced-ejection-fraction disease remains limited and note that earlier GLP-1 receptor agonist trials raised safety concerns[1].

Preserved and reduced ejection fraction are not interchangeable diagnoses. Ejection fraction describes the proportion of blood pumped from the left ventricle with each contraction. FIT-HF requires an ejection fraction of 40% or lower, so its results should answer a narrower question than studies conducted in people whose pumping fraction is preserved.

How the trial is designed

The investigator-initiated study uses two parallel groups, open treatment and blinded outcome assessment. Adults must have a body mass index of at least 30 kg/m2, New York Heart Association class I to III symptoms, stable guideline-directed therapy and an ejection fraction of 40% or lower. Participants are assigned one to one to the two strategies and followed for 52 weeks[1][2].

The semaglutide arm uses weekly subcutaneous treatment with dose escalation toward 2.4 mg. The active comparator starts with roughly 800 kcal per day of total dietary replacement for eight weeks, followed by food reintroduction and dietitian-led weight maintenance. Both groups receive lifestyle counseling and usual heart failure care, and structured physical training begins at week 16[1]. These are research procedures under supervision, not instructions for readers to copy.

An active comparator makes the question more useful than a simple drug-versus-no-treatment design. If the groups achieve different amounts or types of weight loss, however, interpreting a difference in function will require the planned body-composition and physiology measurements rather than attributing everything to the treatment label.

The comparison also tests two packages, not only two mechanisms. Semaglutide is paired with counseling, while the diet arm includes total meal replacement, food reintroduction and continued dietitian support. Structured exercise later applies to both groups. A future difference could therefore reflect adherence, tolerability, achieved weight loss, lean-mass change or the surrounding support as well as pharmacology. The protocol's multimodal measurements are intended to make that interpretation less superficial. Reporting results by assigned group will still be necessary to preserve the value of randomization.

What FIT-HF will measure

The primary endpoint is the adjusted difference between groups in the change in weight-indexed peak oxygen uptake from baseline to week 52. Peak oxygen uptake, or VO2peak, is measured during cardiopulmonary exercise testing and reflects the body's highest measured oxygen use during exertion. Indexing it to body weight adds an interpretive challenge when both interventions are intended to reduce weight[1].

Supportive outcomes include the Kansas City Cardiomyopathy Questionnaire, six-minute walk distance, left-ventricular end-systolic volume on cardiac magnetic resonance imaging, high-sensitivity C-reactive protein and NT-proBNP. The registry also lists safety events, hospital use, cardiac imaging, pulmonary function, body composition, physical activity and metabolic measurements[2]. These measures may help distinguish improved fitness from a mathematical change caused by a smaller body-weight denominator.

The trial is not sized as a definitive cardiovascular-outcomes study. With 100 planned participants and 52 weeks of follow-up, death and hospitalization measures are exploratory rather than a reliable test of whether one strategy prevents major events.

What we do not know

ClinicalTrials.gov listed FIT-HF as recruiting when its record was verified in June 2026, with estimated primary completion in December 2027[2]. Until results are reported, we do not know enrollment completion, treatment adherence, achieved weight loss, changes in VO2peak, adverse events or whether the groups remain comparable after withdrawals.

Open-label treatment means participants know which strategy they receive. Blinded assessors reduce one source of bias, but expectations and adherence can still differ between a weekly medicine and a demanding dietary program. The single protocol also cannot determine whether findings will apply to people with unstable disease, lower body mass index, severe kidney impairment or other groups excluded from enrollment.

For established human semaglutide evidence, use the semaglutide research summary and semaglutide safety overview. The semaglutide regulation section covers approval status by country. FIT-HF may eventually add evidence for a specific heart-failure population, but a registered protocol cannot support treatment claims today.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Has FIT-HF reported results?

No. The 2026 paper is a protocol, and the registry listed the trial as recruiting with estimated completion in December 2027.

What is FIT-HF comparing?

It compares a semaglutide-based weight-loss strategy with an intensive diet-based strategy in adults with obesity and stable heart failure with reduced ejection fraction.

What is the primary outcome?

The primary outcome is the between-group difference in change in weight-indexed peak oxygen uptake from baseline to 52 weeks, measured by cardiopulmonary exercise testing.

Will FIT-HF prove semaglutide prevents heart failure hospitalization?

No. Hospital events are exploratory, and a 100-person, 52-week trial is not a definitive cardiovascular-outcomes study.

Sources

  1. [1]Bäck C et al. FIT-HF: protocol for a randomized controlled trial. Clinical Nutrition ESPEN. 2026. PMID 42988221.Tier 1 · primary↩
  2. [2]ClinicalTrials.gov record NCT06423599: FIT-HF design, arms, outcomes, eligibility and recruitment status.Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars